Frank M. Speetjens

An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

Matteo Salvatore Carlino, Ellen Kapiteijn, Sophie Piperno‐Neumann, Ryan Joseph Sullivan et autres

Abstract Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85−90% of tumors harbor activating GNAQ and GNA11 mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched …

au, nl, fr, us, ch, de, cn (code pays fourni par la source)

Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography

Elissa A. S. Polomski, Frank M. Speetjens, J Wouter Jukema, J C Heemelaar et autres

Treatment of sarcoma includes high-dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines. Consecutive patients diagnosed with sarcoma and treated with anthracyclines were included in …

nl (code pays fourni par la source)

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial – PUMP-IT RCT

EM ter Kuile, NFM Kok, B Westerink, RJ Swijnenburg et autres

BACKGROUND: In patients with colorectal cancer liver metastases (CRLM), resection of the primary tumour and local treatment of liver metastases may offer a chance of cure or long-term survival. Most patients however present with unresectable CRLM. Hepatic arterial infusion pump (HAIP) therapy …

nl, is (code pays fourni par la source)

Therapeutic Strategies Targeting the Tumor–Stromal Microenvironment in Colorectal Cancer: A Narrative Review

Floor Heilijgers, Marie-Christine Bakker, Bente van Hest, Ingrid Franken et autres

Despite advances in colorectal cancer (CRC) treatment, outcomes in advanced disease remain poor. Current therapies mainly target the epithelial compartment of the tumor, yet increasing evidence highlights the tumor microenvironment (TME), particularly the tumor stroma, as a prognostic and potentially predictive factor. …

nl (code pays fourni par la source)

Supplementary Table 2 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Table 2. Adverse Events.

Supplementary Table 4 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Table 4. Results of the ctDNA-NGS analysis.

Supplementary Figure 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Figure 3. Shannon diversity index at baseline for AS subgroups and according to best overall response rate.

Supplementary Figure 2 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Figure 2. Decreased PD-1 expression after cemiplimab treatment in peripheral blood T-cells.

Supplementary Figure 4 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Figure 4. Change in gut microbiome during treatment with cemiplimab.

Supplementary Table 6 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Table 6. Immune cell infiltrate density in responders vs non-responders.

Supplementary Figure 1 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Figure 1. Tumor Mutational Burden.

Supplementary Table 5 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses

Stefan G. van Ravensteijn, Jacco J. de Haan, Hans A. J. Gelderblom, Maikel J.L. Nederkoorn et autres

Supplementary Table 5. Immune cell infiltrate density in tumor vs stroma.